

















1162Favorable Outcomes in Patients Surviving 5 or More
Years after Allogeneic Hematopoietic Stem Cell
Transplantation for Hematologic Malignancies
Robert Quan Le,1 Margaret Bevans,2 Bipin N. Savani,1,3 Sandra A. Mitchell,1,2
Kate Stringaris,1 Eleftheria Koklanaris,1 A. John Barrett1Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for some hematologic
malignancies. As the overall number of survivors continues to increase, studies systematically examining
outcomes in long-term survivors are needed. We studied the clinical and quality-of-life outcomes in
HSCTrecipients surviving 5 or more years from HSCT. Since 1993, 262 patients with hematologic malignan-
cies received a T cell-depleted myeloablative HSCT from an HLA-identical sibling at a single center. Ninety-
two survived beyond 5 years from HSCT (median follow-up 9.4 years, range: 5.1-15.3). Median age at
transplantation was 35 years (range: 10-56). Twenty-two (24%) received a bone marrow transplant, and
70 (76%) received a peripheral blood HSCT. Of the 92 survivors, 60 completed quality-of-life measures.
The main outcomes examined were chronic graft-versus-host-disease, disease relapse, survival, health-
related quality-of-life (HRQL) (Functional Assessment of Cancer Therapy-General), physical and mental
health (SF-36), and symptom experience (Rotterdam SymptomChecklist). Seventy-five (82%) of 92 survivors
no longer required systemic immunosuppressive treatment. Four (4.3%) relapsed with leukemia at a median
of 8.5 years (range: 6.2-14.0) after HSCT. Four (4.3%) died between 7.4 and 13.4 years post-HSCT (1 relapse,
1 lung cancer, 1 pneumonia, 1 brain hemorrhage). Most survivors beyond 5 years had an excellent
performance status with no difference in physical and mental health and higher HRQL scores (P 5 .02)
compared with population norms. Although physical and psychologic symptom distress was low, those
with higher symptom distress experienced inferior HRQL. These results show that 5 or more years after
T cell-depleted HSCT for hematologic malignancy most individuals survive disease free with an excellent
performance status, preserved physical and psychological health, and excellent HRQL.
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Ninety percent of allogeneic hematopoietic stem
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6/j.bbmt.2010.03.005survivors age, more attention must be paid to their
long-term complications [2]. An early study of long-
term HSCT survivors reported an overall survival
(OS) of 31.5% at 10 years in 89 chronic myelogenous
leukemia (CML) patients who had received allogeneic
bone marrow transplantation (BMT) [3]. Ten patients
showed a hematologic relapse between 0.5 and 12
years after BMT, and 1 died in blast crisis 12 years after
BMT [3]. In patients with hematologic malignancies
receiving myeloablative (MA) T cell-depleted periph-
eral blood HSCT we previously reported OS and
relapse-free survival (RFS) of 58% and 46%, respec-
tively, at a median follow-up of 4 years [4].
Of all long-term complications post-HSCT,
chronic graft-verse-host-disease (cGVHD) has been
most intensively studied [4,5]. Prolonged cGVHD is
a risk factor for other complications in long-term
survivors [6], and was found to be a strong prognostic
factor for OS and RFS [4]. Other complications in
this population include pulmonary problems [7], osteo-
porosis [8], infertility [9], hypothyroidism [6], secondary
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and diminished health-related quality of life (HRQL)
[15-17].
Quality of life is recognized as a critical indicator,
along with survival, when considering the efficacy of
new cancer treatments [18]. HRQL is defined as the
extent to which usual or expected physical, emotional,
and social well-being are affected by a medical condi-
tion or its treatment [19]. Overall HRQL measures
suggest a less robust recovery in long-termHSCT sur-
vivors than patients receiving chemotherapy alone
[20], although the level of HRQL may be the same
or better than prior to HSCT [16].
Relative to physical recovery, although some stud-
ies have documented that 5-year survivors return to
a level of physical function comparable to their pre-
transplant baseline [15] or to a level of physical func-
tion on par with that observed in survivors who
received conventional dose chemotherapy only [16],
other research has described impairments in 10-year
survivors that are inferior to population norms
[3,21]. Delayed physical recovery in survivors has
been associated with higher medical risk and
depression before HSCT [15]. Symptomatically
long-term allogeneic HSCT survivors have more
problems than healthy controls [21] and survivors
from chemotherapy [16]. Ten-year survivors reported
a significantly higher number of medical problems
compared to controls [21]. Difficulties with sexual
function and intimacy have been observed across
several studies [20-22]. Other common symptoms
include eye problems [3,20,22], fatigue [3,16,20],
muscleskeletal dysfunction [3,21], pain [3,20], and
difficulties with memory and attention [3,21].
Psychologic and social recovery lags behind phys-
ical recovery in allogeneic HSCT survivors [15], with
emotion dysfunction reported as the most prevalent
problem [20]. Overall, compared to controls [21] or
chemotherapy-only survivors [16], allogeneic HSCT
survivors reported more psychologic and social con-
cerns including those related to role function, financial
difficulties, social function, and vitality. cGVHD
[3,15], less social support before HSCT, and female
sex [15] were associated with greater psychologic and
social dysfunction. Despite these difficulties, studies
indicate that 50% to 84% of survivors return to work
or school [3,15,20].
In 2005, we initiated 2 long-term follow up proto-
cols to further study complications and the trajectory
of recovery in survivors after allogeneic HSCT.
Patients were enrolled in the long-term evaluation
protocol (NHLBI 05-H-0130) at the third annual visit
after transplantation. Annual follow-up visits include
comprehensive clinical evaluation and detailed
quality-of-life assessments (protocol CC 05-CC-
0216). This article describes the relapse, survival, and
quality-of-life outcomes in a large cohort of patientswith hematologic malignancies from a single institu-
tion and surviving 5 or more years after allogeneic
HSCT.PATIENTS AND METHODS
Study Design
A cross-sectional analysis of mortality, disease
relapse, and quality-of-life outcomes was completed
in a sample of 92 patients surviving 5 or more years
following allogeneic HSCT. These data were drawn
from2ongoing natural history studies annually evaluat-
ing cGVHD, major organ dysfunction [6,8], secondary
malignancies, hormonal profile, bone mineral density,
fertility (registration number: NCT0010695), and
quality of life (registration number: NCT00128960)
in HSCT survivors who are 3 or more years following
HSCT. The study was approved by the institutional
review board, and all study subjects provided signed
informed consent for study participation.Patients
Two hundred sixty-two patients with hematologic
disorder received a T cell-depleted HSCT from an
HLA identical sibling between 1993 and 2004. One
hundred twenty-one survivors (46%) were eligible
for participation in the long-term evaluation protocol.
Of these, 92 (35%) surviving 5 or more years after
HSCT were eligible for this study. Quality-of-life
data were available on 60 (65%) subjects literate in
English or Spanish who had a life expectancy of $6
months. Thirty-two patients were not included for
the quality-of-life analysis (11 because of language or
literacy barriers, 2 noncompliance, 1 age\18 year, 1
second HSCT, 14 lost to follow-up, 3 data collection
in process). Demographic data (date of birth, sex,
race, ethnicity, marital status, education level, and
employment status) and clinical data (primary disease,
date of allogeneic HSCT, history, and presence of
acute GVHD (aGVHD) and cGVHD, current immu-
nosuppression, and Eastern Cooperative Oncology
Group performance status) were collected through
self-report and chart review.Transplantation
All patients received anMA preparative regimen of
12-13.6 Gy total-body irradiation (TBI), cyclophos-
phamide 120 mg/kg, with or without fludarabine 125
mg/m2, followed by a T cell-depleted HSCT from
an HLA identical sibling. The stem cell source was
BM in 22 (24%) patients and granulocyte colony stim-
ulating factor (G-CSF)-mobilized peripheral blood
stem cells (PBSCs) in 70 (76%). Cyclosporine was
used as a single agent for graft-versus-host disease
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were graded based on published criteria [23,24].
T Cell Depletion
All MA HSCT were T cell depleted. In the first
protocol (93-H-0212), stem cells were collected after
BM harvesting and were depleted of T cells by elutri-
ation [25]. In protocol 97-H-0099, T cells were
depleted by CD341 selection on the Ceprate SC col-
umn, followed by CD22 selection on a second column
(CellPro, Bothell, WA). After this method became
unavailable, cell products were depleted of T cells
with the Isolex 300i immunomagnetic cell selection
system (Baxter Healthcare, Deerfield, IL) for positive
selection of CD341 cells, followed by negative
selection of T cells using an antibody cocktail of
anti-CD2, anti-CD6, and anti-CD7, as previously
described [26].
Donor Lymphocyte Infusion (DLI)
To prevent relapse and facilitate immune reconsti-
tution, 1 or 2 lymphocyte infusions were scheduled
between days 145 and 1100 or specifically on day
160, excluding patients receiving steroid treatment
for aGVHD grade $2.
Quality-of-Life Outcomes
The Short-Form 36Health Survey (SF-36) version
2 was used to assess physical and mental health using 8
multi-item subscales: Physical Functioning, Role-
Physical, Bodily Pain, General Health, Vitality, Social
Functioning, Role-Emotional, and Mental Health
[27]. Subscales were aggregated to compute the Phys-
ical Component Summary (PCS) and Mental Compo-
nent Summary (MCS). Scores above 50 (SD 10)
indicate physical and mental health higher than the
average for the 1998 U.S. general population
(N5 6742); a value of 3 points suggesting ameaningful
clinical difference.
The Functional Assessment of Cancer Therapy—
General (FACT-G) version 4 was used to measure
cancer-specific HRQL [28]. This 27-item question-
naire evaluates physical, social/family, and emotional
and functional well-being using a scale ranging from
0 to 4. The scores are reported for each subscale and
summed to give an overall HRQL score. Total scores
can range from 0 to 108, with higher scores indicating
better HRQL with a difference of 5 points on the
FACT-G total score associated with a meaningful
clinical difference [29]. Both English and Spanish
versions of the FACT-G have demonstrated good
reliability [30,31].
The Rotterdam Symptom Checklist (RSCL) was
used to measure 30 physical and psychological
symptoms, requiring a response on a 4-point scale
(15 ‘‘not at all’’ to 45 ‘‘very much’’). The RSCL scoreis expressed as physical (range: 23-92), psychological
(range: 7-28), and a total score (range: 30-120) by sum-
ming scores of individual items. Higher scores indicate
more symptom distress. Both English and Spanish
versions of the RSCL show good reliability [32].Statistics
Descriptive statistics were used to summarize the
demographic and clinical characteristics, and quality-
of-life outcome measures including symptom occur-
rence and distress. Symptom occurrence is reported
as symptom prevalence and symptom count. Symptom
prevalence was defined as a rating of $2 for any of the
symptoms on the RSCL. The symptom reported by
the highest percentage of participants was considered
the most prevalent. Symptom count was derived
from the total number of symptoms endorsed as pres-
ent by each participant. Symptom distress was deter-
mined by the mean score for each scale of the RSCL.
Survival curves for OS and primary disease-free
survival (DFS) were plotted using the Kaplan-Meier
method. The OS was defined as the time from
HSCT infusion to death from any cause. DFS was
defined as the time from HSCT infusion to relapse
or death from any cause. The risk factors associated
with long-term outcomes in the patients who survived
the first 5 years post-HSCT were determined by
analyses of clinical and transplant variable characteris-
tics of patients. Two-sided Fisher’s exact tests or
chi-squared tests were used in univariate analyses for
categoric variables. The Mann-Whitney U-test was
used for continuous variables. Logistic regression
was used for multivariate analysis of risk factors.
To examine differences in quality-of-life outcomes
(FACT-G, PCS, MCS) between survivors and U.S.
general population norms, a 1-sample t-test was
computed. An independent t-test was used to deter-
mine differences between sample groups, for example,
participants with and without cGVHD. Relationships
between selected baseline demographic and clinical
characteristics (age at transplant, sex, time since
HSCT, cGVHD, and symptom distress) and quality-
of-life outcomes were examined using Pearson product
moment correlation.
Statistical significance was accepted at value of
P\ .05. The data analyses were performed using the
Statistical Package for Social Sciences (SPSS) version
15 software (SPSS Inc., Chicago, IL) and Prism 4 for
Windows (GraphPad Software, Inc., La Jolla, CA).RESULTS
Patient Characteristics
The characteristics of 92 patients surviving 5 or
more years posttransplant are shown in Table 1. The
Table 1. Characteristics of Patients (n 5 92) Survived 5 or
More Years Post-HSCT: Survivors with (n 5 60) and without
(n 5 32) QOL Survey Completion
N (%)
Variable n 5 92 n 5 60 n 5 32
Age at HSCT, years,
median (range)
35 (10-56) 35 (10-56) 35 (10-51)
Sex
Male 55 (60) 37 (62) 18 (56)
Female 37 (40) 23 (38) 14 (44)
Disease distribution
CML 53 (58) 34 (57) 19 (59)
AML/MDS 30 (33) 20 (33) 10 (31)
ALL 5 (5) 3 (5) 2 (7)
CLL 2 (2) 2 (3) 0 (0)
MM 2 (2) 1 (2) 1 (3)
Stem cell source
Bone marrow 22 (24) 9 (15) 13 (41)
PBSC 70 (76) 51 (85) 19 (59)
h/o acute GVHD
None 58 (63) 31 (52) 27 (84)
Grade I 22 (24) 18 (30) 4 (13)
Grade II-IV 12 (13) 11 (18) 1 (3)
h/o cGVHD
None 28 (30) 10 (17) 18 (56)
Limited 37 (40) 29 (48) 8 (25)
Extensive 27 (30) 21 (35) 6 (19)
cGVHD beyond 5-year f/u
None 75 (82) 49 (82) 26 (81)
Limited 9 (10) 4 (7) 5 (16)
Extensive 8 (8) 7 (11) 1 (3)
IST for cGVHD
beyond 5-year f/u
17 (18) 11 (18) 6 (19)
Relapse beyond 5-year f/u 4 (4) 4 (7) 0 (0)
Mortality beyond 5-year f/u 4 (4) 4 (7) 0 (0)
Follow-up period,
years, median (range)
9.4 (5.1-15.3) 8.2 (4.8-14.3) 11 (5.5-15.3)
CML indicates chronic myelogenous leukemia; MDS, myelodysplastic
syndrome; AML, acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; CLL, chronic lymphocytic leukemia; MM, multiple myeloma;
PBSC, peripheral blood stem cells; GVHD, graft-versus-host disease;
cGVHD, chronic GVHD; IST, immunosuppressive therapy; f/u:
follow-up.
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females was 35 years (range: 10-56 years). The median
follow-up was 9.4 years (range: 5.1-15.3 years). Diag-
noses includedCML (total 53, chronic phase 44, accel-
erated phase 8, blastic phase 1), acute myelogenous
leukemia (AML) (total 5 16, complete remission
[CR]1 5 12, CR2 5 4), myelodysplastic syndrome
[14], acute lymphoblastic leukemia (ALL) (total 5,
CR1 5 1, CR2 5 3, CR3 5 1), chronic lymphocytic
leukemia (CLL) (2), and multiple myeloma (MM)
(2). Of the 92 survivors, 60 survivors completed the
quality-of-life measures (Table 1). The majority
(91.7%) had an excellent performance status (ECOG
5 0) and were employed (61.7) or attending school
(6.7) (Table 2). Five (8%) survivors changed jobs as
a result of the transplant, although all were currently
employed. Five (8%) survivors reported leaving their
job because of the transplant and are currently
retired (n 5 2), a homemaker (n 5 1), on disability
(n 5 1), and attending school full time (n 5 1).GVHD and Immunosuppression
Seventy-five (82%) of 92 survivors had no cGVHD
and no longer required immunosuppressive treatment
(IST) at 5 years following allogeneic HSCT. Seven-
teen (18%) had active cGVHD (limited 9, extensive
8) and were receiving prolonged systemic immunosup-
pressive treatment 5 years post-HSCT. Thirty-four
(37%) of the 92 survivors had a history of aGVHD
(12 with grade II-IV aGVHD), and 64 (70%) had
history of cGVHD (limited 37, extensive in 27) post-
HSCT. In the subset of 60 patients completing the
quality-of-life assessments, only 11 had cGVHD
(4 limited, 7 extensive) and were receiving immuno-
suppressive therapy at the time of survey completion.
Relapse and Mortality beyond 5 Years
For the patients surviving beyond 5 years after
HSCT, the estimated 10- and 15-year post-HSCT
primary DFS was 41% and 34%, respectively
(Figure 1A). Four patients relapsed with an estimated
probability of 6.2% and 17.9%, at 10 and 15 years,
respectively (Figure 1B). The estimated probability
of death was 5.8%, and 16% at 10 and 15 years, respec-
tively (Figure 1B). Table 3 shows the baseline charac-
teristics of the 7 patients who relapsed or died. Four
(2 CML, 1 MDS, and 1 CLL) had a relapse of the
primary disease at a median of 8.5 years (range:
6.2-14.0). None of those relapsed patients had
cGVHD beyond 5 years from transplant, although
2 survivors had history of cGVHD within 5 years
post-HSCT. Four patients (4.3%) died from relapse
of the primary disease, pneumonia, brain hemorrhage,
and secondary lung cancer (Table 3). The median time
to death was 9.6 years (range: 7.4-10.7).
Quality-of-Life Outcomes
There was no difference in physical or mental
health between survivors of allogeneic HSCT and
the U.S. general population based on the SF-36
(Table 4). However, survivors reported a higher total
FACT-G score than the U.S. general population
(P 5 .02). The difference was because of higher func-
tional well-being (P\ .001) and higher social family
well-being (P 5 .03), with no difference in physical
or emotional well-being. To further explore the
impact of age on quality-of-life scores (SF-36,
FACT-G) the sample was divided by age and com-
pared with age-adjusted population norms for clini-
cally meaningful differences. Mean scores were lower
in survivors$55 years of age compared to the popula-
tion specific to physical health (SF-36 PCS) and overall
quality of life (FACT-G total) (Table 4). In addition,
a gradual decline in the median quality of life scores
(SF-36 PCS, J-T test 5 23.579, P\ .001; FACT-G,
J-T test 5 22.838, P 5 .005) was evident as the age
of the survivors in this sample increased. Correlations
Table 2. DemographicsCharacteristics for Survivors (n5 60)
at Survey Completion
Variable n (%)
Age at TOS, years, median (range) 45 (19-68)
Marital status 32 (53.3)
Married 8 (13.3)
Divorced 16 (26.7)











Bachelor’s degree 16 (27.1)
Graduate/professional degree 13 (22.0)
Employment
Full time 31 (51.7)
Part time 6 (10.0)
Student 4 ( 6.7)
Not working 19 (31.7)
TOS indicates time of survey completion.




































































Figure 1. Primary disease-free survival and probability of relapse or
death in patients beyond 5-year post-HSCT. (A) Primary disease-free
survival. Ninety two (35%) of 262 patients survived the first 5-year
post-HSCT. Seventy-three (27.9%) patients had disease relapsed before
5-year-post-HSCT. Eighty patients were primary disease free at the
5-year post-HSCT. (B) Probability of relapse or death. The estimated
probability of primary disease relapse at 10 years and 15 years was
6.2% and 17.9%, respectively. The estimated probability of mortality at
10 years and 15 years was 5.8% and 16%, respectively.
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FACT-G scores revealed that age was inversely
correlated with total FACT-G score and all subscales
except emotional well-being, with younger subjects
reporting better HRQL as well as high physical, func-
tional, and social well-being (Table 5). No other
demographic or clinical variable was significantly
related to quality-of-life outcomes.
Participants reported a median of 8 (range: 0-27)
physical symptoms and a median of 4 (range: 0-7) psy-
chological symptoms. Over half of the sample had 12
or more prevalent symptoms, with the most prevalent
symptoms reported as worry (73.3%), tiredness
(73.3%), lack of energy (63.3%), and tension (60%).
Worries and tiredness were reported as being the
most distressing (mean 2.0 6 0.75, mean 1.9 6 0.71,
respectively). The next most bothersome symptom
was decreased sexual interest (mean 1.90 1 0.98).
Although the overall distress for physical (mean
35.036 9.3) and psychological (mean 126 3.8) symp-
toms was low, survivors experiencing more symptom
distress had lower HRQL (Table 5).
In the subset of 60 patients completing the quality-
of-life assessments only 11 had cGVHD (4 limited, 7
extensive) at the time of survey completion. For all
quality-of-life outcomes, those with cGVHD were
not significantly different from the normative popula-
tion (FACT-G, P5 .35; PCS, P5 .25; MCS, P5 .18).
Despite this finding, which may be because of small
sample size, the difference may be clinically meaning-
ful relative to both FACT-G total score (72.7 6 25.1)
and the PCS (45.1 6 13.2) and MCS (45.5 6 10.4)
scores of the SF-36 with scores approximately 5 points
lower compared the population norms (FACT-G M
80.4 6 15.9; PCS/MCS mean 5 50 6 10). The totalsymptom scores did not differ statistically between
groups; however, those with cGVHD were descrip-
tively higher than those without cGVHD on both
the physical (mean 5 42.1 6 12.9 and 33.4 6 7.6,
respectively) and psychological (mean 5 13.3 6 4.1
and 11.7 6 3.8, respectively) symptoms scales.DISCUSSION
Our findings demonstrate that patients who survive
5 or more years posttransplant experience low rates of
relapse and mortality, with overall preserved quality
of life. The incidence of aGVHD and/or cGVHD
was 30% to 70% in patients with hematologic
diseases undergoing allogeneic HSCT [33-35]. The
development of cGVHD appears to be important in
reducing relapses afterHSCT [36]. Kiss et al. [3] found
that relapses ofCMLoccurred during the entire period
of post-HSCT follow-up. Late relapses also occurred
in CLL patients after 5 years post-HSCT [33]. In our
Table 3. Characteristics of Patients Who Relapsed or Died after Surviving the First 5-Year Post-HSCT





7 35 F MDS/AML 0 0 0 14.0 >14.6
in second remission
121 44 M CLL L 0 0 10.1 > 10.1
receiving chemotherapy
264 15 F CML L 0 0 7.0 >7.9
remission after second
HSCT
292 37 M CML 0 0 0 6.2 7.4
Relapse
99 49 F CLL E 0 0 — 9.4
Pneumonia, sepsis
94 56 M CML L 0 0 — 9.9
Lung Cancer
24 55 M MM E + + — 13.4
Brain Hemorrhage
M indicates male; F, female; MDS, myelodysplastic syndrome; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic my-
elogenous leukemia; MM, multiple myeloma; cGVHD, chronic graft-versus-host disease; E, extensive cGVHD; L, limited cGVHD; IST, immunosuppres-
sive therapy; HSCT, allogeneic hematopoietic stem cell transplantation.
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cGVHD 5-year post-HSCT, this negative association
was not significant (data not shown). Only 1 of the 4
deaths beyond 5-year post-HSCT was because of
relapse of the primary leukemia. Previous studies
have shown that secondary malignancies develop in
long-term follow-up patients post HSCT [11]. How-
ever, although this study did not capture successfully
treated early malignancy (removal of suspicious cuta-
neous lesions and cervical biopsies), of the other deaths
only 1 (pneumonia) appeared to be directly attributable
to the transplant; 1 patient, who was a heavy smoker
died from lung cancer 10 years post-HSCT and 1
died from a cerebrovascular accident.
In this study, quality-of-life outcomes suggest that
the majority of survivors are functioning at a level sim-
ilar to the general population. Although the majority
of patients reported good to excellent HRQL in years
1 to 4 post-HSCT [17], full recovery of physical andTable 4. SF-36 and FACT-G Scale Scores for all QOL Participants a
Total Sample 18-24 25
N 5 60 n 5 7 n
SF-36
PCS Mean SD 49.6 (10.3) 55.2 (5.1) 57.1†
MCS Mean SD 48.2 (9.6) 47.1 (11.5) 48.6
FACT-G Mean SD 85.6* (17.4) 95.0† (10.6) 92.7†
Physical well-being Mean SD 22.8 (4.5) 25.4 (3.0) 24.1
Social well-being Mean SD 20.9* (6.2) 23.6 (5.1) 23.9
Functional well-being Mean SD 21.7* (5.8) 24.3 (4.1) 24.3
Emotional well-being Mean SD 20.1 (4.3) 21.7 (2.7) 20.4
SF-36 indicates Medical Outcomes Study 36-Item Short Form Health Survey; P
FACT-G, Functional Assessment of Cancer Therapy—General; SD, standard d
1SF-36 n 5 6.
2SF-36 n 5 22.
*P < .05 relative to general population norms.
†Exceeds clinically meaningful difference for age-adjusted norms.
‡Below clinically meaningful difference for age-adjusted norms.emotional function appears to be a 3- to 5-year process
[15]. The results of this study support that by 5 years
posttransplant many survivors have experienced a re-
covery that permits them to report values for physical
and mental health and HRQL that are comparable to
healthy populations. Although these findings support
findings from Bush et al. (1995) [20], where over
90% of survivors (range: 6-18.4 years) were leading
a ‘‘full and meaningful’’ life, other studies suggest
that survivors report impaired physical and psycholog-
ical health compared to control groups [3,15] or
patients receiving chemotherapy only [16]. Our find-
ings suggest that older survivors may experience
greater deterioration in their health than the general
population, an observation that supports the need for
life-long monitoring of allogeneic HSCT recipients.
Nevertheless, because subjects in this study may not
be comparable to the general population as there was
no adjustment for sex or other factors that maynd by Age Group for Population Comparison
Age Group, years
-34 35-44 45-54 55-64 65-74
5 71 n 5 16 n 5 232 n 5 5 n 5 2
(2.9) 52.0 (7.7) 47.6 (12.5) 43.0‡ (3.5) 32.2‡ (8.0)
(14.0) 47.7 (8.6) 48.8 (9.3) 47.0‡ (9.5) 50.0 (10.4)
(16.9) 87.7† (14.3) 83.6 (19.0) 78.1 (13.2) 53.0‡ (12.0)
(5.0) 22.3 (4.0) 23.1 (4.6) 20.6 (4.1) 16.5†† (8.4)
(4.0) 22.0 (4.7) 19.3 (6.9) 18.3 (3.7) 10.5‡ (10.6)
(4.9) 22.9 (4.7) 20.9 (6.2) 19.4 (4.6) 10.5‡ (6.4)
(5.3) 19.6 (4.0) 20.3 (4.7) 19.8 (3.0) 15.5‡ (7.8)
CS, Physical component Summary; MCS, Mental Component Summary;
eviation; QOL, quality of life.
Table 5. Relationships (r) between Symptom Distress, Age, and FACT-G Scores (n 5 60)
FACT-G Total PWB SFWB FWB EWB
Rotterdam total score 20.79* 20.82* 20.43† 20.71* 20.73*
Rotterdam physical distress 20.77* 20.83* 20.43† 20.69* 20.69*
Rotterdam psychological distress 20.67* 20.65* 20.35† 20.63* 20.68*
Age at TOS 20.36† 20.26‡ 20.42† 20.35† 20.08
r indicates Pearson Product-Moment Correlation Coefficient; TOS, time of survey completion; FACT-G, Functional Assessment of Cancer Therapy-
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interpreted.
In general, comparisons with other studies are dif-
ficult tomake because of variations in questionnaire se-
lection and administration, and sample characteristics.
This long-term follow-up study differs from previous
reports in several ways. First, in previous studies, ques-
tionnaire administration was not linked with clinical
follow-up by the transplant team. The patients in this
study returned to our institute for a medical evaluation
with 49 of the 60 (82%) survivors who completed the
survey attending a follow-up visit within 60 days of sur-
vey completion—57 (95%) within 2 years. One could
propose that the effect of close follow-up by an inter-
disciplinary transplant team could lead to better
function and HRQL because of the close monitoring
that might better identify and manage complications
decreasing their overall impact on the patient. In
addition, the transplant team might validate a positive
perspective or reframe any concern held by the survivor
creating a response shift [37] or change in the meaning
of their HRQL, which might serve to balance negative
cognitions about the experience of transplants. Second,
one-half of the survivors in this study reported their
ethnicity as Hispanic (non-White), which is unlike
other published reports and the population norms.
The ethnicity is primarily White from both the
SF-36 (84.2%) and the FACT-G (75.9%) population
norms. Culture can influence an individual’s values,
beliefs, and judgments that contribute to HRQL [38],
and should be considered as a factor when interpreting
the findings of this study.
Our findings suggest that older survivors may
experience greater deterioration in their health than
the general population, an observation that supports
the need for life-long monitoring of allogeneic
HSCT recipients. Despite the positive reports of
overall quality of life, survivors report residual effects
of HSCT. Although not causing significant distress,
multiple symptoms are endorsed as prevalent. In this
study, psychological symptoms (eg, worry, tension)
along with fatigue were reported and support the
findings of previous research in transplant survivors
[16,20,21]. In addition, a highly prevalent concern in
this study and across multiple transplant survivorshipstudies is dissatisfaction with sexual function and
intimacy [16,21,20]. Despite these data and findings
that support concern about sexual function during
the first 5 years following allogeneic HSCT [21],
population-specific interventions have yet to be
studied.
cGVHD is often associated with a large number of
symptoms, and correlates with a lower HRQL [39-41]
and impairments in functional performance in patients
post HSCT [42]. Quality of life may also serve as
a measure of successful GVHD prevention and treat-
ment [5,41]. However, all studies did not find an
association between GVHD and quality-of-life out-
comes [43-45]. In this series, 18% of our patients
had cGVHD 5-year post-HSCT or beyond, but
cGVHD was not a significant risk factor for decreased
HRQL. Although these results reveal no statistical dif-
ference between the groups, likely a result of sample
size, clinically meaningful differences appear relative
to physical and mental health, and health-related
QOL. Survivors with cGVHD report lower quality-
of-life scores compared to the sample without
cGVHD and the general population. Two previous
studies have reported that 5- and 10-year survivors
with cGVHD are more likely to have impaired mental
health including depression [3,15]. However, the
overall prevalence of cGVHD in survivors beyond 5
years is not reported or characterized consistently in
long-term (.5 years) survivorship studies; therefore,
the relationship between this population and quality-
of-life outcomes requires further study. Systematic
screening for symptoms in all survivors to target those
individuals experiencing significant symptom burden
for intervention is also suggested.
In summary, although there is significant morbid-
ity and mortality in the first 5 years after allogeneic
HSCT for hematologic malignancy, individuals
surviving 5 years ormore can anticipate a lowmortality
from posttransplant complications. Five or more years
after T cell-depleted HSCT for hematologic malig-
nancy most individuals survive disease free with an
excellent performance status, preserved physical and
mental health, and excellent HRQL. However,
patients with leukemia have a persistent but low chance
of disease recurrence. T cell-depleted HSCT has
Biol Blood Marrow Transplant 16:1162-1170, 2010 1169Long-Term Outcomes after Allogeneic Hematopoietic
Stem Cell Transplantationlower rate of aGVHD, which may have influenced
quality-of-life outcomes. Therefore, our conclusion
may only apply to T cell-depleted HSCT patients.
Although some evidence for cGVHD persists in about
20% of patients, it did not appear to affect the excellent
quality of life that most of our patients experience. The
association between cGVHD severity and specific
cGVHD manifestations and quality-of-life outcomes
requires further study.ACKNOWLEDGMENTS
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